Balchem (BCPC) Scheduled to Post Earnings on Friday

Balchem (NASDAQ:BCPC) is scheduled to issue its quarterly earnings data before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of $0.95 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Balchem (NASDAQ:BCPC) last issued its earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.02. The company had revenue of $228.70 million during the quarter, compared to the consensus estimate of $234.66 million. Balchem had a net margin of 11.77% and a return on equity of 10.69%. Balchem’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.66 EPS. On average, analysts expect Balchem to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Balchem Trading Down 1.5 %

Shares of Balchem stock opened at $138.50 on Friday. The company has a market capitalization of $4.47 billion, a P/E ratio of 41.34, a P/E/G ratio of 4.38 and a beta of 0.71. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.38 and a current ratio of 2.12. The company has a fifty day moving average of $152.40 and a 200 day moving average of $139.85. Balchem has a fifty-two week low of $110.74 and a fifty-two week high of $159.52.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a report on Thursday.

Insiders Place Their Bets

In other Balchem news, SVP Michael Robert Sestrick sold 11,100 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $153.21, for a total value of $1,700,631.00. Following the sale, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, SVP Michael Robert Sestrick sold 11,100 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the sale, the senior vice president now directly owns 6,736 shares in the company, valued at approximately $1,032,022.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Theodore L. Harris sold 34,350 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $154.29, for a total transaction of $5,299,861.50. Following the sale, the chief executive officer now owns 66,412 shares in the company, valued at $10,246,707.48. The disclosure for this sale can be found here. Insiders have sold a total of 76,630 shares of company stock worth $11,843,249 in the last 90 days. 1.77% of the stock is currently owned by corporate insiders.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.